These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 15972609)

  • 1. Aronow's "Should the NCEP III guidelines be changed in elderly and younger persons at high risk for cardiovascular events?" Aim low.
    Nash IS
    J Gerontol A Biol Sci Med Sci; 2005 May; 60(5):599-600; author reply 602. PubMed ID: 15972609
    [No Abstract]   [Full Text] [Related]  

  • 2. Aronow's "Should the NCEP III guidelines be changed in elderly and younger persons at high risk for cardiovascular events?" Cholesterol and the aged: ...and the beat goes on.
    Wilson MM
    J Gerontol A Biol Sci Med Sci; 2005 May; 60(5):600-2; author reply 602. PubMed ID: 15972610
    [No Abstract]   [Full Text] [Related]  

  • 3. Aronow's "Should the NCEP III guidelines be changed in elderly and younger persons at high risk for cardiovascular events?" Commentary.
    Mooradian AD
    J Gerontol A Biol Sci Med Sci; 2005 May; 60(5):598; author reply 602. PubMed ID: 16094774
    [No Abstract]   [Full Text] [Related]  

  • 4. Aronow's "Should the NCEP III guidelines be changed in elderly and younger persons at high risk for cardiovascular events?" Commentary.
    Levy DR; Pearson TA
    J Gerontol A Biol Sci Med Sci; 2005 May; 60(5):597-8; author reply 602. PubMed ID: 16094772
    [No Abstract]   [Full Text] [Related]  

  • 5. Aronow's "Should the NCEP III guidelines be changed in elderly and younger persons at high risk for cardiovascular events?" Hyperlipidemia in seniors: too much, too little, too late?
    Hirth VA
    J Gerontol A Biol Sci Med Sci; 2005 May; 60(5):595-7; author reply 602. PubMed ID: 15972608
    [No Abstract]   [Full Text] [Related]  

  • 6. Aronow's "Should the NCEP III guidelines be changed in elderly and younger persons at high risk for cardiovascular events?" What do we do for the very old?
    Goodwin JS
    J Gerontol A Biol Sci Med Sci; 2005 May; 60(5):593-594; author reply 602. PubMed ID: 15972606
    [No Abstract]   [Full Text] [Related]  

  • 7. Aronow's "Should the NCEP III guidelines be changed in elderly and younger persons at high risk for cardiovascular events?" Preventive gerontology: edging ever closer to the "barrier to immortality".
    Hazzard WR
    J Gerontol A Biol Sci Med Sci; 2005 May; 60(5):594-5; author reply 602. PubMed ID: 15972607
    [No Abstract]   [Full Text] [Related]  

  • 8. Should the NCEP III guidelines be changed in elderly and younger persons at high risk for cardiovascular events?
    Aronow WS
    J Gerontol A Biol Sci Med Sci; 2005 May; 60(5):591-2. PubMed ID: 15972605
    [No Abstract]   [Full Text] [Related]  

  • 9. Stricter cholesterol guidelines broaden indications for the 'statin' drugs.
    Capriotti T
    Medsurg Nurs; 2003 Feb; 12(1):51-7. PubMed ID: 12619600
    [No Abstract]   [Full Text] [Related]  

  • 10. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines.
    Grundy SM; Cleeman JI; Merz CN; Brewer HB; Clark LT; Hunninghake DB; Pasternak RC; Smith SC; Stone NJ;
    J Am Coll Cardiol; 2004 Aug; 44(3):720-32. PubMed ID: 15358046
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines.
    Grundy SM; Cleeman JI; Merz CN; Brewer HB; Clark LT; Hunninghake DB; Pasternak RC; Smith SC; Stone NJ;
    Arterioscler Thromb Vasc Biol; 2004 Aug; 24(8):e149-61. PubMed ID: 15297292
    [TBL] [Abstract][Full Text] [Related]  

  • 12. PCSK9 Inhibitors and Cardiovascular Events.
    Sabatine MS; Wasserman SM; Stein EA
    N Engl J Med; 2015 Aug; 373(8):774-5. PubMed ID: 26295078
    [No Abstract]   [Full Text] [Related]  

  • 13. PCSK9 Inhibitors and Cardiovascular Events.
    Goemann IM; Londero TM; Dora JM
    N Engl J Med; 2015 Aug; 373(8):773-4. PubMed ID: 26287856
    [No Abstract]   [Full Text] [Related]  

  • 14. Further LDL Lowering Could Reduce Cardiovascular Risk.
    Mechcatie E; Rosenberg K
    Am J Nurs; 2018 Nov; 118(11):55-56. PubMed ID: 30358599
    [TBL] [Abstract][Full Text] [Related]  

  • 15. PCSK9 inhibitors reduce cardiovascular events, preliminary data show.
    Mayor S
    BMJ; 2015 Mar; 350():h1508. PubMed ID: 25782694
    [No Abstract]   [Full Text] [Related]  

  • 16. Lowering LDL cholesterol is good, but how and in whom?
    Stone NJ; Lloyd-Jones DM
    N Engl J Med; 2015 Apr; 372(16):1564-5. PubMed ID: 25773740
    [No Abstract]   [Full Text] [Related]  

  • 17. New Studies Do Not Challenge the American College of Cardiology/American Heart Association Lipid Guidelines.
    Hofer TP; Sussman JB; Hayward RA
    Ann Intern Med; 2016 May; 164(10):683-4. PubMed ID: 26857151
    [No Abstract]   [Full Text] [Related]  

  • 18. Updated guidelines support even lower cholesterol levels for at-risk patients.
    Levenson D
    Rep Med Guidel Outcomes Res; 2004 Aug; 15(15):1, 6-7. PubMed ID: 15320342
    [No Abstract]   [Full Text] [Related]  

  • 19. A community-based, randomized trial of ezetimibe added to statin therapy to attain NCEP ATP III goals for LDL cholesterol in hypercholesterolemic patients: the ezetimibe add-on to statin for effectiveness (EASE) trial.
    Pearson TA; Denke MA; McBride PE; Battisti WP; Brady WE; Palmisano J
    Mayo Clin Proc; 2005 May; 80(5):587-95. PubMed ID: 15887425
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Is statin treatment for children safe and effective?].
    Marchetti F; Cannioto Z
    Recenti Prog Med; 2008 Dec; 99(12):599-601. PubMed ID: 19388217
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.